HomeCompareAAPGV vs FCPT

AAPGV vs FCPT: Dividend Comparison 2026

AAPGV yields 11.51% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCPT wins by $6.3K in total portfolio value· pulled ahead in Year 8
10 years
AAPGV
AAPGV
● Live price
11.51%
Share price
$17.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.8K
Annual income
$2,362.57
Full AAPGV calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — AAPGV vs FCPT

📍 FCPT pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAAPGVFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AAPGV + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AAPGV pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AAPGV
Annual income on $10K today (after 15% tax)
$978.14/yr
After 10yr DRIP, annual income (after tax)
$2,008.18/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, FCPT beats the other by $2,900.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AAPGV + FCPT for your $10,000?

AAPGV: 50%FCPT: 50%
100% FCPT50/50100% AAPGV
Portfolio after 10yr
$45.9K
Annual income
$4,068.93/yr
Blended yield
8.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

AAPGV
No analyst data
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AAPGV buys
0
FCPT buys
0
No recent congressional trades found for AAPGV or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAAPGVFCPT
Forward yield11.51%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$42.8K$49.1K
Annual income after 10y$2,362.57$5,775.28
Total dividends collected$17.5K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: AAPGV vs FCPT ($10,000, DRIP)

YearAAPGV PortfolioAAPGV Income/yrFCPT PortfolioFCPT Income/yrGap
1$11,851$1,150.75$11,401$700.92+$450.00AAPGV
2$13,955$1,274.51$13,064$864.84+$891.00AAPGV
3$16,334$1,402.61$15,051$1,072.48+$1.3KAAPGV
4$19,012$1,534.36$17,442$1,337.22+$1.6KAAPGV
5$22,012$1,669.06$20,340$1,677.08+$1.7KAAPGV
6$25,359$1,806.01$23,880$2,116.57+$1.5KAAPGV
7$29,078$1,944.49$28,241$2,689.36+$837.00AAPGV
8← crossover$33,198$2,083.84$33,660$3,442.07$462.00FCPT
9$37,745$2,223.40$40,456$4,439.95$2.7KFCPT
10$42,750$2,362.57$49,063$5,775.28$6.3KFCPT

AAPGV vs FCPT: Complete Analysis 2026

AAPGVStock

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Full AAPGV Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this AAPGV vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AAPGV vs SCHDAAPGV vs JEPIAAPGV vs OAAPGV vs KOAAPGV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.